Australia-based biotech PolyActiva receives AUS$9.2m ($9.5m) series B from a consortium of new and existing investors to develop glaucoma and osteoarthritis treatments.

The other investors in the B round included Japan state and corporate-backed Innovation Network, Japan-based industrial group Hosiden and venture capital firm Clean Pacific Ventures.

Founded in 2010, Avraham said it had now raised $14.7m to test patients with Alzheimer's disease after a $9m round in April 2010.

Founded in 2010, Avraham said it had now raised $14.7m to to test patients with Alzheimer's disease after a $9m round in April 2010.

In December, SynapDx raised $6m in its series B round from venture capital firms North Bridge Venture Partners and General Catalyst Partners.

German-based RegioHelden has raised an undisclosed amount in series B funding.